# QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct07342283/  
OnCo record `nct07342283` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Affiliated Hospital of Nantong University, now recruiting.

## Summary

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07342283 by Affiliated Hospital of Nantong University, with a registry enrolment figure of 30 participants, started 2026-02-25 and due to reach its primary completion in 2027-12-25. Interventions recorded: Immunotherapy combined with chemotherapy. Conditions listed: Triple Negative Breast Cancer (TNBC). Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07342283
- Phase: 2
- Setting: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
- Sponsor: Affiliated Hospital of Nantong University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07342283: https://clinicaltrials.gov/study/NCT07342283

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07342283.json